Nucleocytoplasmic Shuttling of Smad Proteins
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Product Data Sheet
KAMIYA BIOMEDICAL COMPANY Rev. 082707 PRODUCT DATA SHEET Product: Bone Morphogenetic Protein Receptor Type IA (BMPR1A), (human recombinant) Cat. No.: BP-026 (10 µg) Synonyms: Reconstitution: BMPR-1A, BMP-R1A, BMPR1A, BMR1A, It is recommended to reconstitute the lyophilized CD292, CD-292, Serine/threonine-protein kinase recombinant human BMPR1A in sterile PBS at receptor R5, SKR5, Activin receptor-like kinase not less than 100 µg/mL, which can then be 3, ALK-3, ACVRLK3, EC 2.7.11.30, CD292 further diluted to other aqueous solutions. antigen. Storage: Background: Lyophilized protein is stable for at least 3 weeks The bone morphogenetic protein (BMP) at room temperature. Long term storage should receptors are a family of transmembrane be below -18 °C, desiccated. Upon serine/threonine kinases that include the type I reconstitution, human recombinant BMPR1A receptors BMPR1A and BMPR1B and the type II should be stored at 4°C between 2-7 days, and receptor BMPR2. These receptors are also for future use below -18°C. For long term closely related to the activin receptors, ACVR1 storage it is recommended to add a carrier and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF- protein (0.1% HSA or BSA). Aliquot to avoid betas and activins transduce their signals freeze/thaw cycles. through the formation of heteromeric complexes with two different types of serine (threonine) Purity: kinase receptors: type I receptors of about 50-55 >90% determined by RP-HPLC, and SDS-PAGE. kDa and type II receptors of about 70-80 kDa. Type II receptors bind ligands in the absence of Biological Activity: type I receptors, but they require their respective Measured by its ability to inhibit recombinant type I receptors for signaling, whereas type I human BMP-2 induced alkaline phosphatase receptors require their respective type II production by C2C12 myogenic cells. -
Activation of Smad Transcriptional Activity by Protein Inhibitor of Activated STAT3 (PIAS3)
Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) Jianyin Long*†‡, Guannan Wang*†‡, Isao Matsuura*†‡, Dongming He*†‡, and Fang Liu*†‡§ *Center for Advanced Biotechnology and Medicine, †Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, and ‡Cancer Institute of New Jersey, 679 Hoes Lane, Piscataway, NJ 08854 Communicated by Allan H. Conney, Rutgers, The State University of New Jersey, Piscataway, NJ, November 17, 2003 (received for review August 22, 2003) Smad proteins play pivotal roles in mediating the transforming of many transcription factors through distinct mechanisms. growth factor  (TGF-) transcriptional responses. We show in this PIAS1 and PIAS3 bind and inhibit STAT1 and STAT3 DNA- report that PIAS3, a member of the protein inhibitor of activated binding activities, respectively (19, 20). PIASx␣ and PIASx STAT (PIAS) family, activates TGF-͞Smad transcriptional re- were identified through interactions with the androgen receptor sponses. PIAS3 interacts with Smad proteins, most strongly with and the homeodomain protein Msx2, respectively (21, 22). Smad3. PIAS3 and Smad3 interact with each other at the endog- PIASx␣ and PIASx inhibit IL12-mediated and STAT4- enous protein level in mammalian cells and also in vitro, and the dependent gene activation (23). PIAS1, PIAS3, PIASx␣, and association occurs through the C-terminal domain of Smad3. We PIASx also regulate transcriptional activation by various ste- further show that PIAS3 can interact with the general coactivators roid receptors (21, 24–26). PIASy has been shown to antagonize p300͞CBP, the first evidence that a PIAS protein can associate with the activities of STAT1 (27), androgen receptor (28), p53 (29), p300͞CBP. -
A Truncated Bone Morphogenetic Protein Receptor Affects Dorsal-Ventral Patterning in the Early Xenopus Embryo ATSUSHI SUZUKI*, R
Proc. Nati. Acad. Sci. USA Vol. 91, pp. 10255-10259, October 1994 Developmental Biology A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo ATSUSHI SUZUKI*, R. ScoTT THIESt, NOBORU YAMAJIt*, JEFFREY J. SONGt, JOHN M. WOZNEYt, KAZUO MURAKAMI§, AND NAOTO UENO*1 *Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan; tGenetics Institute Inc., 87 Cambridge Park Drive, Cambridge, MA 02140; tYamanouchi Pharmaceutical Co., Ltd., Tokyo 103, Japan; and Institute of Applied Biochemistry, University of Tsukuba, Tsukuba, Ibaraki 305, Japan Communicated by Igor B. Dawid, July 13, 1994 ABSTRACT Bone morphogenetic proteins (BMPs), which corresponding proteins are present in developing Xenopus are members of the trnsming growth factor 13 (TGF-I) embryos, and overexpression of BMP4 in the embryos superfamily, have been implicated in bone formation and the enhances the formation of ventral mesoderm (8-11). Animal regulation ofearly development. To better understand the roles cap ectoderm treated with a combination of BMP4 and of BMPs in Xenopus laevis embryogenesis, we have cloned a activin also results in the formation of ventral mesoderm, cDNA coding for a serine/threonine kinase receptor that binds suggesting that BMP-4 is a ventralizing factor that acts by BMP-2 and BMP-4. To analyze its function, we attempted to overriding the dorsalizing signal provided by activin (8, 9). block the BMP signaling pathway in Xenopus embryos by using Therefore, activin and BMP-4 are thought to play important a domint-negative mutant of the BMP receptor. When the roles in the dorsal-ventral patterning of embryonic meso- mutant receptor lacking the putative serine/threonine kinase derm. -
Tgfβ-Regulated Gene Expression by Smads and Sp1/KLF-Like Transcription Factors in Cancer VOLKER ELLENRIEDER
ANTICANCER RESEARCH 28 : 1531-1540 (2008) Review TGFβ-regulated Gene Expression by Smads and Sp1/KLF-like Transcription Factors in Cancer VOLKER ELLENRIEDER Signal Transduction Laboratory, Internal Medicine, Department of Gastroenterology and Endocrinology, University of Marburg, Marburg, Germany Abstract. Transforming growth factor beta (TGF β) controls complex induces the canonical Smad signaling molecules which vital cellular functions through its ability to regulate gene then translocate into the nucleus to regulate transcription (2). The expression. TGFβ binding to its transmembrane receptor cellular response to TGF β can be extremely variable depending kinases initiates distinct intracellular signalling cascades on the cell type and the activation status of a cell at a given time. including the Smad signalling and transcription factors and also For instance, TGF β induces growth arrest and apoptosis in Smad-independent pathways. In normal epithelial cells, TGF β healthy epithelial cells, whereas it can also promote tumor stimulation induces a cytostatic program which includes the progression through stimulation of cell proliferation and the transcriptional repression of the c-Myc oncogene and the later induction of an epithelial-to-mesenchymal transition of tumor induction of the cell cycle inhibitors p15 INK4b and p21 Cip1 . cells (1, 3). In the last decade it has become clear that both the During carcinogenesis, however, many tumor cells lose their tumor suppressing and the tumor promoting functions of TGF β ability to respond to TGF β with growth inhibition, and instead, are primarily regulated on the level of gene expression through activate genes involved in cell proliferation, invasion and Smad-dependent and -independent mechanisms (1, 2, 4). -
5956.Full.Pdf
Cancer Therapy: Preclinical Radiation and Transforming Growth Factor-B Cooperate inTranscriptional Activation of the Profibrotic Plasminogen Activator Inhibitor-1 Gene Jurre Hageman,1Bart J. Eggen,3 Tom Rozema,1, 2 Kevin Damman,1 Harm H. Kampinga,1and Robert P. Coppes1, 2 Abstract Radiation-induced fibrosis is an important side effect in the treatment of cancer. Profibrotic pro- teins, such as plasminogen activator inhibitor-1 (PAI-1), transforming growth factor-h (TGF-h), and tissue type inhibitor of metalloproteinases-1 (Timp-1), are thought to play major roles in the development of fibrosis via the modulation of extracellular matrix integrity.We did a detailed anal- ysis of transcriptional activation of these profibrotic genes by radiation and TGF-h. Irradiation of HepG2 cells led to a high increase in PAI-1mRNA levels and a mild increase in Timp-1mRNA lev- els. In contrast,TGF-h1and Smad7 were not increased. Radiation and TGF-h showed strong co- operative effects in transcription of the PAI-1 gene. The TGF-b1 gene showed a mild cooperative activation, whereas Timp-1and Smad7 were not cooperatively activated by radiation and TGF-h. Analysis using the proximal 800 bp of the human PAI-1promoter revealed a dose-dependent increase of PAI-1levels between 2 and 32 Gy g-rays that was independent of latent TGF-h acti- vation. Subsequent site-directed mutagenesis of the PAI-1promoter revealed that mutation of a p53-binding element abolished radiation-induced PAI-1 transcription. In line with this, PAI-1 was not activated in p53-null Hep3B cells, indicating that p53 underlies the radiation-induced PAI-1activation and the cooperativity with theTGF-h/Smad pathway. -
Expression of SMAD Proteins, TGF-Beta/Activin Signaling
original article Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues Expressão de proteínas SMAD, mediadores da sinalização de TGF-beta/activina, em tecidos de tiroide humana Sílvia E. Matsuo1, Ana Paula Z. P. Fiore1, Simone M. Siguematu1, Kátia N. Ebina1, Celso U. M. Friguglietti1, Maria C. Ferro2, Marco A. V. Kulcsar1,3, Edna T. Kimura1 ABSTRACT Objective: To investigate the expression of SMAD proteins in human thyroid tissues since 1 Departamento de Biologia the inactivation of TGF-β/activin signaling components is reported in several types of cancer. Celular e do Desenvolvimento, Phosphorylated SMAD 2 and SMAD3 (pSMAD2/3) associated with the SMAD4 induce the signal Instituto de Ciências Biomédicas, Universidade de São Paulo (ICB- transduction generated by TGF-β and activin, while SMAD7 inhibits this intracellular signaling. USP), São Paulo, SP, Brazil Although TGF-β and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors 2 Departamento de Morfologia e express high levels of these proteins. Materials and methods: The protein expression of SMADs Patologia, Pontifícia Universidade Católica (PUC), Sorocaba, SP, Brazil was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas 3 Departamento de Cirurgia by immunohistochemistry. Results: The expression of pSMAD2/3, SMAD4 and SMAD7 was de Cabeça e Pescoço, USP, observed in both benign and malignant thyroid tumors. Although pSMAD2/3, SMAD4 and São Paulo, SP, Brazil SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions. Conclusions: The finding of SMADs expression in thyroid cells and the presence of pSMAD2/3 and SMAD4 proteins in the nucleus of tumor cells indicates propagation of TGF-β/activin signaling. -
An Activin Receptor IIA Ligand Trap Corrects Ineffective Erythropoiesis In
ARTICLES An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia Michael Dussiot1–5,13, Thiago T Maciel1–5,13, Aurélie Fricot1–5, Céline Chartier1–5, Olivier Negre6,7, Joel Veiga4, Damien Grapton1–5, Etienne Paubelle1–5, Emmanuel Payen6,7, Yves Beuzard6,7, Philippe Leboulch6,7, Jean-Antoine Ribeil1–4,8, Jean-Benoit Arlet1–4, Francine Coté1–4, Geneviève Courtois1–4, Yelena Z Ginzburg9, Thomas O Daniel10, Rajesh Chopra10, Victoria Sung11, Olivier Hermine1–4,12 & Ivan C Moura1–5 The pathophysiology of ineffective erythropoiesis in b-thalassemia is poorly understood. We report that RAP-011, an activin receptor IIA (ActRIIA) ligand trap, improved ineffective erythropoiesis, corrected anemia and limited iron overload in a mouse model of b-thalassemia intermedia. Expression of growth differentiation factor 11 (GDF11), an ActRIIA ligand, was increased in splenic erythroblasts from thalassemic mice and in erythroblasts and sera from subjects with b-thalassemia. Inactivation of GDF11 decreased oxidative stress and the amount of a-globin membrane precipitates, resulting in increased terminal erythroid differentiation. Abnormal GDF11 expression was dependent on reactive oxygen species, suggesting the existence of an autocrine amplification loop in b-thalassemia. GDF11 inactivation also corrected the abnormal ratio of immature/mature erythroblasts by inducing apoptosis of immature erythroblasts through the Fas–Fas ligand pathway. Taken together, these observations suggest that ActRIIA ligand traps may have therapeutic relevance in b-thalassemia by suppressing the deleterious effects of GDF11, a cytokine which blocks terminal erythroid maturation through an autocrine amplification loop involving oxidative stress and a-globin precipitation. β-thalassemia is a common inherited hemoglobinopathy that is differentiation both in vitro8 and in vivo9, is involved in the regula- characterized by impaired or absent β-globin chain production and tion of stress responses in the spleen of adult mice10. -
Sensing Relative Signal in the Tgf-Β/Smad Pathway PNAS PLUS
Sensing relative signal in the Tgf-β/Smad pathway PNAS PLUS Christopher L. Fricka,1, Clare Yarkaa, Harry Nunnsa, and Lea Goentoroa,1 aDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125 Edited by Arup K. Chakraborty, Massachusetts Institute of Technology, Cambridge, MA, and approved February 3, 2017 (received for review July 12, 2016) How signaling pathways function reliably despite cellular varia- Smad4. In their heteromeric form, the Smad proteins are retained tion remains a question in many systems. In the transforming more strongly in the nucleus through reduced export rate, as well as, growth factor-β (Tgf-β) pathway, exposure to ligand stimulates as proposed recently (11), accelerated import rate. Thus, ligand nuclear localization of Smad proteins, which then regulate target activation leads to a net accumulation of the Smad complex in gene expression. Examining Smad3 dynamics in live reporter cells, the nucleus, where it regulates target genes. we found evidence for fold-change detection. Although the level The Tgf-β pathway is a particularly interesting system for of nuclear Smad3 varied across cells, the fold change in the level of testing for fold-change detection because it is known that the nuclear Smad3 was a more precise outcome of ligand stimulation. expression levels of its components vary considerably from cell to The precision of the fold-change response was observed through- cell. A recent study using proximity ligation assay in fixed cells out the signaling duration and across Tgf-β doses, and significantly revealed that the levels of Smad3/4 and Smad2/4 complexes vary increased the information transduction capacity of the pathway. -
TGF-Β Signaling
biomolecules Review TGF-β Signaling Kalliopi Tzavlaki and Aristidis Moustakas * Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-18-4714732; Fax: +46-18-4714441 Received: 18 February 2020; Accepted: 20 March 2020; Published: 23 March 2020 Abstract: Transforming growth factor-β (TGF-β) represents an evolutionarily conserved family of secreted polypeptide factors that regulate many aspects of physiological embryogenesis and adult tissue homeostasis. The TGF-β family members are also involved in pathophysiological mechanisms that underlie many diseases. Although the family comprises many factors, which exhibit cell type-specific and developmental stage-dependent biological actions, they all signal via conserved signaling pathways. The signaling mechanisms of the TGF-β family are controlled at the extracellular level, where ligand secretion, deposition to the extracellular matrix and activation prior to signaling play important roles. At the plasma membrane level, TGF-βs associate with receptor kinases that mediate phosphorylation-dependent signaling to downstream mediators, mainly the SMAD proteins, and mediate oligomerization-dependent signaling to ubiquitin ligases and intracellular protein kinases. The interplay between SMADs and other signaling proteins mediate regulatory signals that control expression of target genes, RNA processing at multiple levels, mRNA translation and nuclear or cytoplasmic protein regulation. This article emphasizes signaling mechanisms and the importance of biochemical control in executing biological functions by the prototype member of the family, TGF-β. Keywords: extracellular matrix; phosphorylation; receptor serine/threonine kinase; signal transduction; SMAD; transcription; transforming growth factor-β; ubiquitylation 1. -
Clinical Significance of Prognostic and Predictive Markers in Colorectal
The Pharmacogenomics Journal (2002) 2, 209–216 2002 Nature Publishing Group All rights reserved 1470-269X/02 $25.00 www.nature.com/tpj CLINICAL IMPLICATION multiple genetic abnormalities are Clinical significance of prognostic accumulated over time during the pro- gression from adenoma to adenocarci- and predictive markers in colorectal noma (Figure 1).1 Mutations in genes such as the Kirsten-ras (K-ras), aden- cancer omatous polyposis coli (APC), deleted in colon cancer (DCC) and the p53 DB Longley, U McDermott and PG Johnston tumour suppressor gene are the most common genetic alterations found in Department of Oncology, Cancer Research Centre, Queen’s University Belfast, Belfast, sporadic CRC. Approximately 5% of Northern Ireland CRC is inherited and familial aden- omatous polyposis (FAP) and heredi- tary non-polyposis colon cancer The Pharmacogenomics Journal (2002) 2, fication and microsatellite instability (HNPCC) are the most well-charac- 209–216. doi:10.1038/sj.tpj.6500124 (MSI). In addition, the expression of terized syndromes.2 FAP is caused by individual genes can be assessed at the mutations in the APC gene, whereas INTRODUCTION levels of mRNA and protein using the 90% of HNPCC cases are caused by Colorectal cancer (CRC) is the second techniques of real-time reverse tran- mutations in genes involved in mis- most common cause of cancer death scription PCR and immunohistochem- match repair (MMR) leading to in the US. Approximately 130 000 new istry (IHC) respectively. The ultimate microsatellite instability (MSI). In cases of CRC are diagnosed in the US goal of this research is the tailoring of addition, 10–15% of sporadic cases of each year with an annual mortality of treatment to the molecular pheno- CRC have mutations in MMR genes. -
IRF3 Prevents Colorectal Tumorigenesis Via Inhibiting the Nuclear Translocation of Β-Catenin
ARTICLE https://doi.org/10.1038/s41467-020-19627-7 OPEN IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin Miao Tian1,7, Xiumei Wang1,7, Jihong Sun2,7, Wenlong Lin1, Lumin Chen2, Shengduo Liu3, Ximei Wu 4, ✉ ✉ Liyun Shi5, Pinglong Xu 3, Xiujun Cai 6 & Xiaojian Wang 1 Occurrence of Colorectal cancer (CRC) is relevant with gut microbiota. However, role of IRF3, a key signaling mediator in innate immune sensing, has been barely investigated in CRC. 1234567890():,; Here, we unexpectedly found that the IRF3 deficient mice are hyper-susceptible to the development of intestinal tumor in AOM/DSS and Apcmin/+ models. Genetic ablation of IRF3 profoundly promotes the proliferation of intestinal epithelial cells via aberrantly activating Wnt signaling. Mechanically, IRF3 in resting state robustly associates with the active β- catenin in the cytoplasm, thus preventing its nuclear translocation and cell proliferation, which can be relieved upon microbe-induced activation of IRF3. In accordance, the survival of CRC is clinically correlated with the expression level of IRF3. Therefore, our study identifies IRF3 as a negative regulator of the Wnt/β-catenin pathway and a potential prognosis marker for Wnt-related tumorigenesis, and describes an intriguing link between gut microbiota and CRC via the IRF3-β-catenin axis. 1 Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003 Hangzhou, China. 2 Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 310016 Hangzhou, China. 3 The MOE Key Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, 310058 Hangzhou, China. -
A Highly Selective Chemical Probe for Activin Receptor-Like Kinases ALK4 and ALK5
bioRxiv preprint doi: https://doi.org/10.1101/2020.01.23.916502; this version posted January 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5 Thomas Hanke1, Jong Fu Wong2, Benedict-Tilmann Berger1, Ismahan Abdi1, Lena Marie Berger1, Roberta Tesch1, Claudia Tredup1, Alex N. Bullock2, Susanne Müller1, Stefan Knapp1 1Institute for Pharmaceutical Chemistry and Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany. 2Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK. *Correspondence: [email protected] Abstract: The transforming growth factor beta-receptor I/activin receptor-like kinase 5 (TGFBR1/ALK5) and its close homologue ALK4 are receptor protein kinases associated with the development of diverse diseases, including cancer, fibrosis, heart diseases and dysfunctional immune response. Therefore, ALK4/5 are among the most studied kinases and several inhibitors have been developed. However, current commercially available inhibitors either lack selectivity or have not been comprehensively characterized, limiting their value for studying ALK4/5 function in cellular systems. To this end, we report the characterization of the 2-oxo-imidazopyridine, TP-008, a potent chemical probe with dual activity for ALK4 and ALK5 as well as the development of a matching negative control compound. TP-008 has excellent cellular potency and strongly abrogates phosphorylation of the substrate SMAD2 (mothers against decapentaplegic homolog 2).